James P Raftery

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. pmc Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial
    James P Raftery
    Health Economics Facility, Health Services Management Centre, University of Birmingham, Birmingham B15 2RT
    BMJ 330:707. 2005
  2. ncbi request reprint Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand
    James P Raftery
    Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK
    Med J Aust 188:26-8. 2008
  3. pmc Registration of noncommercial randomised clinical trials: the feasibility of using trial registries to monitor the number of trials
    James Raftery
    University of Southampton, Southampton, UK
    Trials 13:140. 2012
  4. pmc "Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation
    Louise Dent
    University of Southampton Clinical Trials Unit MP131, University of Southampton, SO16 6YD, UK
    Trials 12:83. 2011
  5. pmc DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT
    Rob Jones
    Section of Old Age Psychiatry, The University of Nottingham, A Floor, South Block, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Trials 10:57. 2009
  6. pmc An evaluation of the cost-effectiveness of booklet-based self-management of dizziness in primary care, with and without expert telephone support
    Lucy Yardley
    School of Psychology, University of Southampton, Highfield, Southampton, UK
    BMC Ear Nose Throat Disord 9:13. 2009
  7. pmc Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists
    James Raftery
    Wessex Institute for Health R and D, School of Medicine, University of Southampton, Southampton, UK
    Trials 10:15. 2009
  8. pmc Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
    James Raftery
    Wessex Institute for Health R and D, Medical School, University of Southampton, Southampton, UK
    Br J Ophthalmol 91:1244-6. 2007
  9. pmc The cheaper drug, bevacizumab, should be referred to NICE
    James P Raftery
    BMJ 334:381-2. 2007
  10. pmc SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]
    Deborah McCahon
    BMC Fam Pract 4:11. 2003

Collaborators

  • Ruairidh Milne
  • Andrew Clegg
  • Andrew Lotery
  • J W Mant
  • Gregory Yh Lip
  • Kate Jolly
  • Louise Dent
  • Rob Jones
  • Lucy Yardley
  • Deborah McCahon
  • Rod Taylor
  • Craig Ritchie
  • David Findlay
  • Peter Bentham
  • Mary Griffin
  • Tony Johnson
  • Debbie King
  • JOHN O'BRIEN
  • Robin Jacoby
  • Richard Gray
  • Roy Jones
  • Patrick Phillips
  • Ian McKeith
  • Peter Passmore
  • Sube Banerjee
  • Heinrich Lamprecht
  • Rob Howard
  • Paul Little
  • Rupert McShane
  • Ajay Macharouthu
  • Martin Knapp
  • Fiona Barker
  • Jessica Adams
  • Tom Dening
  • Alistair Burns
  • Alan Hughes
  • Ed Juszczak
  • Sarah Kirby
  • Jill Mann
  • Caroline Onions
  • Clive Ballard
  • Anna Morris
  • Stephen Pearson
  • Ashley Baldwin
  • Bart Sheehan
  • Paul Koranteng
  • Mark Mullee
  • James Lindesay
  • Clive Holmes
  • Richard Brown
  • Bob Barber
  • Richard F D Hobbs
  • David A Fitzmaurice
  • Teresa F Allan
  • Christopher J Fuller
  • Ellen T Murray

Detail Information

Publications11

  1. pmc Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial
    James P Raftery
    Health Economics Facility, Health Services Management Centre, University of Birmingham, Birmingham B15 2RT
    BMJ 330:707. 2005
    ..To establish the cost effectiveness of nurse led secondary prevention clinics for coronary heart disease based on four years' follow up of a randomised controlled trial...
  2. ncbi request reprint Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand
    James P Raftery
    Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK
    Med J Aust 188:26-8. 2008
    ..All three countries made exceptions in order to fund drugs of poor cost-effectiveness for some "dread" diseases, but some drugs for less alarming conditions were either not funded or heavily restricted...
  3. pmc Registration of noncommercial randomised clinical trials: the feasibility of using trial registries to monitor the number of trials
    James Raftery
    University of Southampton, Southampton, UK
    Trials 13:140. 2012
    ..Formation of the NIHR in 2006 and increased research spending by the Department of Health may have increased the number of noncommercial trials but no data are available...
  4. pmc "Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation
    Louise Dent
    University of Southampton Clinical Trials Unit MP131, University of Southampton, SO16 6YD, UK
    Trials 12:83. 2011
    ..Measures of sufficiency and stability may indicate whether this is true.Objectives: To show how evidence accumulated on centre-based versus home-based cardiac rehabilitation, including estimates of sufficiency and stability..
  5. pmc DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT
    Rob Jones
    Section of Old Age Psychiatry, The University of Nottingham, A Floor, South Block, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Trials 10:57. 2009
    ..The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil...
  6. pmc An evaluation of the cost-effectiveness of booklet-based self-management of dizziness in primary care, with and without expert telephone support
    Lucy Yardley
    School of Psychology, University of Southampton, Highfield, Southampton, UK
    BMC Ear Nose Throat Disord 9:13. 2009
    ..The aim of this trial is to evaluate two new alternative models of delivery that may be more feasible and cost-effective...
  7. pmc Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists
    James Raftery
    Wessex Institute for Health R and D, School of Medicine, University of Southampton, Southampton, UK
    Trials 10:15. 2009
    ..The aims were to review relevant guidelines and to collate and analyse views of clinical trialists on the role of payments and other factors that motivated clinicians to join clinical trials...
  8. pmc Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
    James Raftery
    Wessex Institute for Health R and D, Medical School, University of Southampton, Southampton, UK
    Br J Ophthalmol 91:1244-6. 2007
    ..Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD...
  9. pmc The cheaper drug, bevacizumab, should be referred to NICE
    James P Raftery
    BMJ 334:381-2. 2007
  10. pmc SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]
    Deborah McCahon
    BMC Fam Pract 4:11. 2003
    ..Patient self-management is a logical progression from the primary care model. This study will be the first to randomise non-selected patients in primary care, to either self-management or standard care...
  11. pmc Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]
    Kate Jolly
    Department of Public Health and Epidemiology, Public Health Building, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
    BMC Cardiovasc Disord 3:10. 2003
    ..Evidence of the effectiveness of home-based cardiac rehabilitation remains limited. This trial evaluates the effectiveness and cost-effectiveness of home-based compared to hospital-based cardiac rehabilitation...